[go: up one dir, main page]

PL3842425T3 - Nowy inhibitor będący pochodną chinoliny - Google Patents

Nowy inhibitor będący pochodną chinoliny

Info

Publication number
PL3842425T3
PL3842425T3 PL19851019.0T PL19851019T PL3842425T3 PL 3842425 T3 PL3842425 T3 PL 3842425T3 PL 19851019 T PL19851019 T PL 19851019T PL 3842425 T3 PL3842425 T3 PL 3842425T3
Authority
PL
Poland
Prior art keywords
quinoline derivative
novel quinoline
derivative inhibitor
inhibitor
novel
Prior art date
Application number
PL19851019.0T
Other languages
English (en)
Inventor
Frank Wu
Zhonghui WAN
Original Assignee
Transthera Sciences (Nanjing), Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transthera Sciences (Nanjing), Inc. filed Critical Transthera Sciences (Nanjing), Inc.
Publication of PL3842425T3 publication Critical patent/PL3842425T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/80Acids; Esters in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/056Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL19851019.0T 2018-08-24 2019-08-23 Nowy inhibitor będący pochodną chinoliny PL3842425T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201810971406 2018-08-24
CN201811403888 2018-11-23
CN201910126817 2019-02-20
CN201910490783 2019-06-06
PCT/CN2019/102230 WO2020038460A1 (zh) 2018-08-24 2019-08-23 一种新型的喹啉衍生物抑制剂

Publications (1)

Publication Number Publication Date
PL3842425T3 true PL3842425T3 (pl) 2024-08-19

Family

ID=69591988

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19851019.0T PL3842425T3 (pl) 2018-08-24 2019-08-23 Nowy inhibitor będący pochodną chinoliny

Country Status (14)

Country Link
US (1) US20220073496A1 (pl)
EP (1) EP3842425B1 (pl)
JP (2) JP2021536436A (pl)
KR (1) KR102845791B1 (pl)
CN (1) CN110857293B (pl)
AU (1) AU2019323455B9 (pl)
BR (1) BR112021003447A2 (pl)
CA (1) CA3109891A1 (pl)
ES (1) ES2985569T3 (pl)
PL (1) PL3842425T3 (pl)
PT (1) PT3842425T (pl)
SG (1) SG11202101622VA (pl)
TW (1) TWI726397B (pl)
WO (1) WO2020038460A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202115028A (zh) * 2019-09-24 2021-04-16 大陸商南京藥捷安康生物科技有限公司 雜環衍生物及其用途
JP2022551422A (ja) 2019-09-26 2022-12-09 エグゼリクシス, インコーポレイテッド ピリドン化合物およびタンパク質キナーゼの調節における使用の方法
KR20230012473A (ko) * 2020-03-30 2023-01-26 허치슨 메디파르마 리미티드 아미드 화합물 및 그의 용도
CN114127987B (zh) 2020-05-07 2024-06-14 株式会社Lg新能源 具有降低的水分反应性的高镍电极片及其制造方法
IT202100022682A1 (it) * 2021-09-01 2023-03-01 Luigi Frati Derivati pirimidinici e loro uso nel trattamento di tumori
WO2024046292A1 (zh) 2022-08-30 2024-03-07 药捷安康(南京)科技股份有限公司 喹啉衍生物抑制剂的晶型及其制备方法及用途
CN115894198B (zh) * 2022-11-04 2024-05-17 浙江永太科技股份有限公司 Qulipta的关键中间体1-(2,3,6-三氟苯基)丙烷-2-酮的制备方法
CN117534655B (zh) * 2023-11-13 2024-08-30 复旦大学 一种喹诺酮类化合物及其制备方法和用途
CN119074713B (zh) * 2024-08-07 2025-10-31 中国医学科学院药用植物研究所 L-nrb在制备治疗肌萎缩侧索硬化症的药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
MX2010007525A (es) * 2008-01-22 2010-08-18 Vernalis R&D Ltd Derivados de indolil-piridona que tienen actividad inhibitoria de la cinasa 1 de punto de control.
TWI365185B (en) * 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
WO2011017142A1 (en) * 2009-08-06 2011-02-10 Merck Patent Gmbh Novel bicyclic urea compounds
WO2011139891A1 (en) * 2010-04-29 2011-11-10 Deciphera Pharmaceuticals, Llc Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites
WO2013022766A1 (en) * 2011-08-05 2013-02-14 Flynn Gary A Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
DK2780338T3 (en) * 2011-11-14 2016-12-19 Ignyta Inc Uracil AS AXL- AND C-MET kinase inhibitors
CA2863515C (en) * 2012-01-31 2018-02-27 Daiichi Sankyo Company, Limited Pyridone derivatives
CA2879542A1 (en) * 2012-07-25 2014-01-30 Salk Institute For Biological Studies Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine
WO2014145015A2 (en) * 2013-03-15 2014-09-18 Deciphera Pharmaceuticals, Llc Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities
US9914731B2 (en) * 2013-12-26 2018-03-13 Ignyta, Inc. Pyrazolo[1,5-a]pyridine derivatives and methods of their use
JP6708130B2 (ja) * 2014-12-25 2020-06-10 小野薬品工業株式会社 キノリン誘導体
CN107667101B (zh) * 2015-04-14 2021-07-30 奎利恩特有限公司 作为tam rtk抑制剂的喹啉衍生物
CN106467541B (zh) * 2015-08-18 2019-04-05 暨南大学 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
MX2019014021A (es) * 2017-05-24 2020-08-17 Abbisko Therapeutics Co Ltd Derivado de n-(azaarilo)ciclo lactam-1-carboxamida, metodo de preparacion del mismo y uso del mismo.
CN110520416B (zh) * 2017-10-26 2022-06-03 北京越之康泰生物医药科技有限公司 多取代吡啶酮类衍生物、其制备方法及其医药用途
JP7377798B2 (ja) * 2017-11-24 2023-11-10 南京明徳新薬研発有限公司 c-MET/AXL阻害剤としてのウラシル系化合物
UY38349A (es) * 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
US20200216416A1 (en) * 2019-01-03 2020-07-09 Array Biopharma Inc. Quinoline compounds as inhibitors of tam and met kinases

Also Published As

Publication number Publication date
CN110857293A (zh) 2020-03-03
CN110857293B (zh) 2023-01-10
JP2021536436A (ja) 2021-12-27
TW202021589A (zh) 2020-06-16
AU2019323455A1 (en) 2021-04-01
US20220073496A1 (en) 2022-03-10
SG11202101622VA (en) 2021-03-30
PT3842425T (pt) 2024-07-02
TWI726397B (zh) 2021-05-01
KR20210049862A (ko) 2021-05-06
EP3842425B1 (en) 2024-05-22
EP3842425A1 (en) 2021-06-30
AU2019323455B2 (en) 2024-07-11
KR102845791B1 (ko) 2025-08-13
JP2024056742A (ja) 2024-04-23
EP3842425A4 (en) 2022-05-18
ES2985569T3 (es) 2024-11-06
AU2019323455B9 (en) 2024-10-24
BR112021003447A2 (pt) 2021-05-18
WO2020038460A1 (zh) 2020-02-27
CA3109891A1 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
SG11202106520VA (en) Kif18a inhibitors
ZA201905811B (en) Novel inhibitors
SG11202101622VA (en) Novel quinoline derivative inhibitor
IL275207A (en) An oxyfluoropiperidine derivative as a kinase inhibitor
SG11202004918XA (en) Amino-fluoropiperidine derivative as kinase inhibitor
SG11202010024UA (en) New quinoline derivatives
GB201705971D0 (en) Inhibitor compounds
EP3447058A4 (en) NEW WIDE SPECTRUM LACTAMASE INHIBITOR
IL281634A (en) Diacosocyclobutanylamino-3-hydroxy-picoline modified amide and its use as a CCR6 inhibitor
IL274036A (en) Novel pyrazolo-pyrrolo-pyrimidine-dione compounds as P2X3 inhibitors
GB201819126D0 (en) Inhibitor compounds
IL290964A (en) A 2-aminoquinazolinone derivative
SG11202102379XA (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
SG11202005870RA (en) Novel mtor inhibitor compounds
IL276013A (en) pi4kiiibeta inhibitors
SG11202007979UA (en) Dihydrochromene derivative
SG11202006837XA (en) Dihydroindolizinone derivative
GB201819136D0 (en) Inhibitor compounds
GB201708999D0 (en) Recrystallization Inhibitor
HK40062253A (en) Kif18a inhibitors
GB201809939D0 (en) Eastase inhibitor
GB201908044D0 (en) Dopamine-B-Hydroxylase inhibitors
GB201812462D0 (en) Inhibitors
HK40058334A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
GB201905476D0 (en) MAPA4K4 Inhibitors